Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Breast Cancer Metastatic × fluzoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 2 Breast Neoplasms 2 Sarcoma, Ewing 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplasm Metastasis 1 Her-2 Negative Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Breast Cancer Metastatic 1 Advanced Solid Tumors 1

Interventions

dalpiciclib 2 trastuzumab deruxtecan 1 pyrotinib 1 patritumab deruxtecan 1 olaparib 1 fluzoparib 1 apatinib 1 Ga(III)-DOTATOC 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05759546 2024-02-06

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Fudan University

Phase 2 Recruiting

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡